Laserfiche WebLink
IVES'TAR <br /> QUALITY CARE,INC. <br /> c. If the exposed individual was previously vaccinated and a known responder <br /> (adequate serum antibody levels of >_ 10mIU/ml) and the source is positive, <br /> negative, untested or unknown: <br /> • No treatment is indicated <br /> d. If the exposed individual was previously vaccinated and a known non- <br /> responder (serum antibody levels of < 10mIU/mi) and the source is HbsAG <br /> positive, untested or unknown (if the source is HbsAG negative, no treatment <br /> is indicated): <br /> • Administer HBIG x2 or HBIG x1 and initiate re-vaccination series <br /> e. If the exposed individual was previously vaccinated, but antibody status <br /> unknown and the source is HbsAG positive (if source is HbsAg negative, no <br /> treatment is indicated): <br /> • Test exposed individual for antibody to Hepatitis B surface antigen; if <br /> adequate, no treatment is indicated <br /> • If inadequate, HBIG x1 and vaccine booster <br /> f. If the exposed individual was previously vaccinated, but antibody response <br /> unknown and the source is untested or unknown: <br /> • Test exposed individual for antibody to Hepatitis B surface antigen; if <br /> adequate, no treatment is indicated <br /> • If inadequate, initiate re-vaccination series <br /> 12. The exposed employee is provided with the source individual's test results and with <br /> information about applicable disclosure laws and regulations concerning the identity <br /> and infectious status of the source individual, e.g., laws protecting confidentiality. <br /> 13. When indicated, the employee is offered: <br /> • Post-exposure HIV prophylaxis, counseling; and <br /> • Evaluation of reported illnesses. <br /> 14. Study the circumstances of the exposure incident to determine: <br /> • Engineering controls in use at the time, <br /> • Work practices followed, <br /> • A description of the device being used, <br /> 3/14/01 CL-IP-3051 Post-Exposure Evaluation Page 3 of 4 <br />